Vectura pursues JV for cost-conscious China entry
This article was originally published in Scrip
After deliberating "for some time" how best to enter the market, Vectura has settled on a joint venture model for the commercialization of its technologies in China, where it sees attractive and increasing opportunities for growth.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.